Research and development commitments in an integrated plasma collection and plasma fractionation environment

Plasma fractionation has emerged as one of the most scientifically demandin g fields in the biopharmaceutical area. Producing safe plasma derivatives i mplies the development, use, and proper understanding of sensitive testing technologies to detect infection markers in starting plasma. It also requir es the implementation of carefully selected, nondenaturing, efficient plasm a protein purification and viral reduction technologies that do not alter t he physiological functions and clinical potential of plasma proteins. Succe ss in this field can be achieved only by a strong commitment to sustain con stant research and development of projects targeting the production of safe r and innovative plasma products.